Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
CircularClimateClimate ChangeEmissionEnvironmentEnvironmentalLifecycleMaterialsNatureOffsetPackagePackagingPandemicRaw MaterialsRegenerativeScarcityToxicWasteAccessAffordabilityBenefitsBlackCalifornia Consumer Privacy ActCommunityCultureCustomerCyberCybersecurityData PrivacyData SecurityDeathDemographicsDisabilityDiversityDrug PricingEmployeeEmployee EngagementEmployee RetentionEngagementEthnicGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHuman CapitalHuman ResourcesIncidentInjuriesInjuryMinorityPerquisitesPrivacyProduct QualityRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkillsSocialSocietyStakeholderSupplierSupply ChainSupply Chain ManagementTalentTrainingUnionWomenWorkersWorkforceAnti-corruptionAssessmentAssuranceAttorneys GeneralAuditBoard OversightBonusBriberyChronicClass Action LawsuitClassifiedClassified BoardClawbackCommitmentCorporate GovernanceCorporate PurposeDepartment ofESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentIndependent Lead DirectorInnovationInnovativeInvestigationLawsuitLeadershipLitigationLong-termMajorityMissionOther Public Company BoardsOverboardingOverseeOversightPerquisitePlaintiffPledgingPoison PillProcurementPurposeQuality StandardR&DRecoupReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationSpecial MeetingStockholder OutreachStrategySustainabilityTargetsTaxTenureTransparencyTransparentVoting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

IVERIC bio, Inc. ("IVERIC") held its 2021 annual meeting of stockholders on May 19, 2021. The following is a summary of the matters voted on at that meeting.

(a) IVERIC’s stockholders elected Dr. Mark Blumenkranz, Mr. Axel Bolte and Dr. Cal Roberts as Class II directors to serve until the 2024 annual meeting of stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders’ vote for the election of such Class II directors were as follows:

Mark S. Blumenkranz, M.D.65,025,60793,65313,535,860
Axel Bolte64,143,908975,35213,535,860
Calvin W. Roberts, M.D.64,894,969224,29113,535,860

(b) IVERIC’s stockholders approved a non-binding, advisory proposal on the compensation of IVERIC’s named executive officers, as described in the definitive proxy statement for the 2021 annual meeting of stockholders. The results of the stockholders’ vote for such matter were as follows:


(c) IVERIC’s stockholders ratified the selection of Ernst & Young LLP as IVERIC’s independent registered public accounting firm for the current fiscal year. The results of the stockholders’ vote for such matter were as follows: